NeuroDefend, a novel Chinese medicine, attenuates amyloid-β and tau pathology in experimental Alzheimer's disease models

Ashok Iyaswamy, Senthil Kumar Krishnamoorthi, Ju Xian Song, Chuan Bin Yang, Venkatapathy Kaliyamoorthy, Huan Zhang, Sravan G. Sreenivasmurthy, Sandeep Malampati, Zi Ying Wang, Zhou Zhu, Benjamin Chun Kit Tong, King Ho Cheung, Jia Hong Lu, Siva Sundara Kumar Durairajan*, Min Li*

*Corresponding author for this work

Research output: Contribution to journalJournal articlepeer-review

30 Citations (Scopus)


Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder. Amyloid-β (Aβ) and hyper-phosphorylated tau accumulation are accountable for the progressive neuronal loss and cognitive impairments usually observed in AD. Currently, medications for AD offer moderate symptomatic relief but fail to cure the disease; hence development of effective and safe drugs is urgently needed for AD treatment. In this study, we investigated a Chinese medicine (CM) formulation named NeuroDefend (ND), for reducing amyloid β (Aβ) and tau pathology in transgenic AD mice models. Regular oral administration of ND improved cognitive function and memory in 3XTg-AD and 5XFAD mice. In addition, ND reduced beta-amyloid precursor protein (APP), APP C-terminal fragments (CTF-β/α), Aβ and 4G8 positive Aβ burden in 3XTg-AD and 5XFAD mice. Furthermore, ND efficiently reduced the levels of insoluble phospho-tau protein aggregates and AT8 positive phospho tau neuron load in 3XTg-AD mice. Hence, ND could be a promising candidate for the treatment of AD in humans.

Original languageEnglish
Pages (from-to)132-146
Number of pages15
JournalJournal of Food and Drug Analysis
Issue number1
Early online date8 Oct 2019
Publication statusPublished - Jan 2020

Scopus Subject Areas

  • Food Science
  • Pharmacology

User-Defined Keywords

  • Alzheimer's disease
  • Aβ-plaque
  • Chinese medicine
  • NeuroDefend
  • Neurofibrillary tangles


Dive into the research topics of 'NeuroDefend, a novel Chinese medicine, attenuates amyloid-β and tau pathology in experimental Alzheimer's disease models'. Together they form a unique fingerprint.

Cite this